NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
ABACAVIR SULFATE; LAMIVUDINE (abacavir sulfate; lamivudine) by Viatris (2) is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ABACAVIR SULFATE; LAMIVUDINE is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) for treatment of HIV-1 infection in adults and pediatric patients weighing at least 6 kg. The combination works by inhibiting reverse transcriptase, blocking viral replication and reducing HIV viral load. This is an oral tablet formulation designed to simplify regimen adherence in HIV-positive populations.
Pre-Launch
Pre-launch stage presents opportunity for launch planning, market access, and early commercial strategy roles; team buildout ongoing with undefined near-term revenue trajectory.
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Worked on ABACAVIR SULFATE; LAMIVUDINE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.